Sierra et al. [35] found that ATRA can ameliorate the inflammatory response during initiation of diabetic nephropathy by inhibiting the expressions of proinflammatory factors (IL-1 β, IL-6, IL-13, IL-2 and TNF-α). The gene discussed is IL6; the disease is diabetic kidney disease.